Is bone marrow biopsy obligatory in all patients with non-Hodgkin's lymphoma?

Acta Haematologica

Volumn 118, Issue 1, 2007, Pages 61-64

  Bairey, Osnat ^a   Shpilberg, Ofer ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Aggressive lymphoma; Bone marrow biopsy; Extranodal; Indolent lymphoma; International Prognostic Index; Non Hodgkin's lymphoma; Stage

Indexed keywords

ARTICLE; BLEEDING; BONE MARROW BIOPSY; CANCER STAGING; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; HUMAN; INVASIVE PROCEDURE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; STRESS;

BIOPSY, NEEDLE; BONE MARROW; BONE MARROW EXAMINATION; DECISION MAKING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, NON-HODGKIN; MALE; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UNNECESSARY PROCEDURES;

EID: 34347354363     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102589     Document Type: Article

References (27)

1. Juneja SK, Wolf MM, Cooper IA: Value of bilateral bone marrow biopsy specimens in non-Hodgkin's lymphoma. J Clin Pathol 1991;43:630-632.
2. McKenna RW, Hernandez JA: Bone marrow in malignant lymphoma. Hematol Oncol Clin North Am 1988;2:617-635.
3. Foucar K, McKenna RW, Frizzera G, Brunning RD: Bone marrow and blood involvement by lymphoma in relationship to the Lukes-Collins classification. Cancer 1982; 49:888-897.
4. Bartl R, Frisch B, Burkhardt R, Kettner G, Mahl G, Fateh-Moqhadam A, Sund M: Assessment of bone marrow histology in the malignant lymphomas (non-Hodgkin's): correlation with clinical factors for diagnosis, prognosis, classification and staging. Br J Haematol 1982;51:511-530.
5. Lee WI, Lee JH, Kim IS, Lee KN, Kim SH: Bone marrow involvement by non-Hodgkins lymphoma. J Korean Med Sci 1994;9: 402-408.
6. Conlan MG, Bast M, Armitage JO, Weisenburger DD: Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990;8:1163-1172.
7. Vanhelleputte P, Nijs K, Delforge M, Evers G, Vanderschueren S: Pain during bone marrow aspiration: prevalence and prevention. J Pain Symptom Management 2003;26:860-886.
8. Dunlop TJ, Deen C, Lind S, Voyle RJ, Prichard JG: Use of combined oral narcotic and benzodiazepine for control of pain associated with bone marrow examination. South Med J 1999;92:477-480.
9. Bain BJ: Morbidity associated with bone marrow aspiration and trephine biopsy - a review of UK data for 2004. Haematologica 2005;91:1295-1296.
10. Bain BJ: Bone marrow biopsy morbidity: review of 2003. J Clin Pathol 2005;58:406-408.
11. Morley NJ, Makris M: Bone marrow biopsy related hemorrhage and low molecular weight heparin. Br J Haematol 2003;123: 562.
12. The International Non-Hodgkin's Lymphoma Prognostic Factor Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
13. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E: Follicular Lymphoma International Prognostic Index. Blood 2004;104:1258-1265.
14. Moller MB, Pederson NT, Christensen BE: Diffuse large B-cell lymphoma: clinical implication of extranodal versus nodal presentation - a population based study of 1575 cases. Br J Haematol 2004;2:151-159.
15. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Groqan TM, LeBlanc M, Carlin S, Chase E, Fisher RI: Chemotherapy alone compared to chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-26.
16. Lim ST, Tao M, Cheung YB, Rajan S, Mann B: Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy? Ann Oncol 2005;16:215-218.
17. Simon R, Durrleman S, Hoppe RT, Bonadonna G, Bloomfield CD, Rudders RA, Cheson BD, Berard CW: The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas. Ann Intern Med 1988;109:939-945.
18. Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, Simon RM, DeVita VT: Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1980;50:2699-2707.
19. Buckstein R, Lim W, Franssen E, Imrie KL: CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Leukemia Lymphoma 2003;44:955-962.
20. Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rosec C, Tilly H, Sonet A, Lederlin P, Attal M, Briere J, Reyes F: Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol 2000;11:685-690.
21. Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A: For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol 1998;9:191-194.
22. Batchelor T, Loeffler S: Primary CNS lymphoma. J Clin Oncol 2006;24:1281-1288.
23. Marcus R: Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. Semin Oncol 2005;32:36-43.
24. Diehl V, Specht L, Pfistner B, Coiffier B, Hoppe R, Cheson B: Response criteria in malignant lymphoma revisited - a proposal of the international harmonization project of the German competence network of malignant lymphomas. Hematology 2006;2:151-153.
25. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stoobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V: Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-586.
26. Pakos EE, Fotopoulos AD, Ioannidis JP: 18FFDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a metaanalysis. J Nucl Med 2005;46:958-963.
27. Armitage JO: Defining the stages of aggressive non-Hodgkin's lymphoma: a work in progress. N Engl J Med 2005;352:1250-1252.